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combined with precision radiotherapy and chemotherapy in 
our orthotopic GBM model is currently being evaluated.  
Conclusions: The results of this will be presented. 
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Purpose/Objective: To evaluate the impact of two TBI 
schedules on the risk of relapse and transplant-related 
mortality (TRM) in 61 patients with acute leukemia who 
received HLA matched T-cell depleted allogeneic 
hematopoietic stem cell transplantation (matched HSCT). 
Materials and Methods: 29 males and 32 females (median 
age 48 years; range 20-66) were enrolled from January 1999 
to October 2013. 41 (67.2 %) patients had acute myeloid 
leukemia (AML) and 20 (32.8%) acute lymphoid leukemia 
(ALL). 43 patients were in first complete remission (CR1), 8 
in CR2 and 10 had persistent disease. Patients in CR1 and CR2 
were analyzed as one group. Group 1 (31 patients) 
conditioning was a hyperfractionated schedule (HTBI) (1.2 Gy 
3 times a day for 4 days up to 14.4 Gy; lung dose 9 Gy) from 
day -10 to day -7. Group 2 (30 patients) conditioning was a 
single TBI (STBI) schedule (8 Gy, at a median dose-rate of 
10.7 cGy/min, lung dose 4 Gy) delivered on day -9. All 
patients received Thiotepa (10 mg/kg) and Fludarabine (160 
mg/m2 ) consecutively from day -6 to day -3 after HTBI and 
from day -8 to day -2 after STBI. Anti-thymocyte globulin 
(ATG) was administered to 27 patients to strengthen the 
immunosuppressive effect of the conditioning regimen. No 
immunosuppressive drug was administered post-transplant as 
prophylaxis for Graft versus Host Disease (GvHD). All patients 
received anti-bacterial, antifungal, antiviral, anti-
Pneumocystis prophylaxis.  
Results: Median follow-up was 63.53 months (range 2.53-
186.77). No patient rejected the transplant. Acute GvHD 
occurred in 11/61 patients (18%; 8 Grade I-II and 3 Grade III). 
Four were in the HTBI group and 7 in the STBI group; no cases 
of chronic GvHD were observed. Relapse developed in 18 
patients (29.5%). The 5-year probability of relapse was 28% 
(CI 95% 0.17-0.41). Univariate analysis showed disease 
impacted significantly on the cumulative incidence of relapse 
with AML relapsing less than ALL (p=0.035). Overall, HTBI 
tended to be better than STBI (p=0.11). Age, disease stage, 
ATG administration, GvHD did not impact upon the risk of 
relapse. The Fine and Gray model with disease and TBI as 
main factors confirmed the results of the univariate analysis. 
With a different parametrization an even lower risk of 
relapse in AML patients who received HTBI not STBI (p=0.015) 
was found. TRM occurred in 10 patients (16,39%, 4/31 after 
HTBI; 6/30 after STBI). Causes of death were infection in 8 
patients and GvHD in 2 patients. The 5-year probability of 
TRM was 18%. Univariate analysis showed age, disease and 
disease stage, ATG administration, TBI schedule, GvHD had 
no impact on TRM.  
Conclusions: In AML patients HTBI in the conditioning 
regimen for HLA matched T-depleted HSCT is more 
efficacious than STBI in reducing the risk of relapse. 
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Purpose/Objective: Even if brain cancer is a rare disease, its 
rising trend of the last three decades with its poor survival 
rate needs further analysis, possibly based on large 
randomized trials conducted on population-based data. 
Moreover, because of few available standard therapeutic 
strategies the identification of prognostic and predictive 
factors is a recent field of interest towards personalized 
treatments. The effort should be the storage of a large 
database coming from several datasets avoiding semantic 
difference and in concepts description through the adoption 
of a uniform language. Therefore our aim is to build a brain 
cancer ontology to standardize data, creating a consistent 
and specific large database in order to produce predictive 
models, useful to implement a Decision Support System 
(DSS).  
Materials and Methods: A multi-professional team, involving 
medical doctors, a mathematician and an engineer, was 
employed to design an ontology in which concepts and data 
related to brain cancer are standardized and organized in 
order to create a storage of knowledge and data. Three 
different levels of analysis were considered to classify the all 
concepts. Some of them are related to general information in 
common with other cancer types, others are brain cancer 
related. In a next step, 'atomic' data type (i.e. integer, real, 
datatime) or structured data type (i.e.: a DICOM file, an XML 
structure, etc...) were added in order to provide a range for 
the predicates. 
Results: More than 200 clinical, bio-molecular, 
neuropsychological and imaging features related to brain 
cancer were selected and classified according to three 
different levels. The first, the Registry level, includes general 
and epidemiological information as patient code, sex, age, 
gender, ethnicity, site and histology of the tumor, 
institution, the death and its cause. This level can probably 
be shared with ontologies related to other cancer sites. The 
second, the Procedure level, reports variables related to the 
muti-discipinary management of patients and brain cancer 
specific. It includes information about clinical presentation of 
the tumor, about surgery, radiotherapy or chemotherapy 
treatment, about outcomes evaluation and toxicity. We 
represented toxicities according to CTCAEv4 and RTOG scales 
and we provided also a description of therapeutic 
relationship between the two standards. The third is the 
Research level considering the elements useful for advanced 
